FSHD University – FORTITUDE Trial interim results

1:00 PM ET | noon CT | 11:00 AM MT | 10:00 AM PT

This World FSHD Day join the Avidity Biosciences team as they share an update on the FORTITUDE^TM study on FSHD University. The Avidity team, joined by Dr. Jeffrey Statland, University of Kansas Medical Center and FORTITUDE trial investigator, will present in-progress results from the FORTITUDE Phase 1/2 clinical trial evaluating AOC 1020 for adults with FSHD. AOC 1020 is an antibody-oligonucleotide conjugate (AOC^TM) being developed to target the root cause of FSHD. The primary goal of the FORTITUDE study is to evaluate the safety and tolerability of AOC 1020. Avidity designed FORTITUDE in partnership with patients, caregivers, advocates, and key physicians in the field to ensure the study best meets the needs of the FSHD community. Avidity looks forward to recognizing World FSHD Day and welcoming you to the webinar.